Trial reportRheumatology (Oxford, England)2026
Longitudinal changes in patient characteristics as drivers of clinical outcomes in the Early Undifferentiated PolyArthritis (EUPA) cohort.
Trial report in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveWe investigated whether gradual clinical changes in RA patients diagnosed over two decades contributed to their improving outcomes during follow-up.
methodsA total of 840 consecutive early RA patients were recruited in the Early Undifferentiated PolyArthritis (EUPA) cohort and assessed up to 5 years. Recruitment was categorized into three periods: (1) preBIO (1998-2004), (2) INNOV (2005-2010) and (3) T2Tp (2011-2022). Inverse probability of treatment weighting (IPTW) was used to account for baseline variations over time periods. Multivariate generalized estimating equations (GEEs) with repeated measures identified predictors of outcomes.
resultsThe recruitment periods comprised 245, 266 and 329 recruited patients, respectively. After IPTW, baseline characteristics became largely similar across periods. Use of high-dose MTX and biologics markedly increased after 2005, remaining similar (MTX) or increasing slightly (biologics) in T2Tp relative to INNOV periods. Corticosteroid tapering accelerated and became more complete in the T2Tp period. In multivariable analyses, after balancing baseline characteristics and accounting for changes in diagnostic and therapeutic strategies over time, recruitment after 2011 remained strongly associated with faster and more prevalent ACR/EULAR remission but not with erosive status over follow-up. Despite improved clinical outcomes, improvement curves over 5 years for functional status and other patient-reported outcomes (PROs) remained unchanged across the three periods.
conclusionsCompared with the INNOV period, patients recruited after 2011 presented with milder baseline characteristics and showed evidence for an amplified response to treatment during follow-up, contributing to higher remission rates. Nonetheless, improvements of function and other PROs remained similar across recruitment periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.